The Experts below are selected from a list of 285 Experts worldwide ranked by ideXlab platform

Roland E. Schmieder - One of the best experts on this subject based on the ideXlab platform.

  • Comparison of Therapeutic Studies on Regression of Left Ventricular Hypertrophy
    Advances in Experimental Medicine and Biology, 1997
    Co-Authors: Roland E. Schmieder, Markus P Schlaich
    Abstract:

    In numerous studies Left Ventricular Hypertrophy has been clearly established to be a strong, blood-pressure independent risk factor for cardiovascular morbidity and mortality. In fact, increased echocardiographic Left Ventricular mass has been shown to predict cardiovascular complications not only in patients with hypertension, but also in the general population. Preliminary data revealed that regression of Left Ventricular Hypertrophy indeed reduces cardiovascular complications. As a consequence, regression of Left Ventricular Hypertrophy by drug treatment has emerged as a desirable goal in patients with echocardiographically determined Left Ventricular Hypertrophy. These findings raised the question, whether certain antihypertensive drugs differ in their ability to reduce Left Ventricular mass. To resolve this issue several comparative studies and some meta-analyses have been carried out.

  • Hypertensive heart disease--significance of Left Ventricular Hypertrophy.
    Journal of cardiovascular pharmacology, 1992
    Co-Authors: Roland E. Schmieder
    Abstract:

    One of the earliest structural changes in the heart adapting to hypertension is Left Ventricular Hypertrophy, which can now be exactly measured by echocardiography. Left Ventricular Hypertrophy increases the incidence of coronary artery disease, heart failure, and sudden death severalfold, independent of the blood pressure levels. Left Ventricular Hypertrophy requires specific antihypertensive therapy that controls both high blood pressure and increased Left Ventricular mass. Preliminary data from clinical studies indicate that regression of Left Ventricular Hypertrophy leads to a better cardiovascular prognosis. Sympatholytic substances, angiotensin-converting enzyme (ACE) inhibitors, and calcium antagonists are antihypertensive agents that effected adequate reductions in blood pressure as well as regression of Left Ventricular Hypertrophy.

  • Hypertensive heart disease--significance of Left Ventricular Hypertrophy.
    Journal of Cardiovascular Pharmacology, 1992
    Co-Authors: Roland E. Schmieder
    Abstract:

    One of the earliest structural changes in the heart adapting to hypertension is Left Ventricular Hypertrophy. which can now be exactly measured by echocardiography.Left Ventricular Hypertrophy increases the incidence of coronary artery disease, heart failure, and sudden death severalfold, independent of the blood pressure levels. Left Ventricular Hypertrophy requires specific antihypertensive therapy that controls both high blood pressure and increased Left Ventricular mass

Sidorenko Ba - One of the best experts on this subject based on the ideXlab platform.

  • Left Ventricular Hypertrophy in hypertension. Part II. Prognostic value of Left Ventricular Hypertrophy
    Kardiologiia, 2020
    Co-Authors: Preobrazhenskiĭ Dv, Alekhin Mn, Sidorenko Ba, Talantbek Batyraliev, Stetsenko Tm
    Abstract:

    : This part of review is based on results of prospective studies of prognostic value of Left Ventricular Hypertrophy defined by electro- or echocardiographical criteria. Increased risk of cardiovascular complications has been found to be associated with Left Ventricular Hypertrophy detected not only by voltage ECG criteria but also by ST-segment and T-wave changes in Left precordial leads. Left Ventricular myocardial mass is an independent factor of prognosis too. Prognostic significance of Left Ventricular Hypertrophy depends on echocardiographical criteria used and on age, sex, race of patients and presence of coronary heart disease. Unfavorable prognostic significance of Left Ventricular Hypertrophy becomes evident after several years of follow-up. Concentric Left Ventricular remodeling is also associated with increased risk of cardiovascular complications, however its value for prognosis is inferior to that of Left Ventricular Hypertrophy.

  • Left Ventricular Hypertrophy in Hypertension. Part III. Reversibility of Left Ventricular Hypertrophy During Treatment With Antihypertensive Drugs
    Kardiologiia, 2020
    Co-Authors: Preobrazhenskiĭ Dv, Alekhin Mn, Sidorenko Ba, Talantbek Batyraliev, Stetsenko Tm
    Abstract:

    : Results of prospective trials of effects of various antihypertensive drugs on Left Ventricular Hypertrophy in patients with hypertensive disease are reviewed. According to 2 meta-analyses angiotensin converting enzyme inhibitors are most effective inducers of regression of Left Ventricular Hypertrophy. However in comparative randomized trials in patients with hypertension ability of diuretics, lipophilic beta-adrenoblockers, long-acting calcium antagonists, and angiotensin receptor blockers to cause regression of Left Ventricular Hypertrophy was not inferior to that of angiotensin converting enzyme inhibitors.

  • Hereditary factors and Left Ventricular Hypertrophy
    Kardiologiia, 2020
    Co-Authors: Brazhnik Va, Zateĭshchikov Da, Sidorenko Ba
    Abstract:

    : Left Ventricular Hypertrophy (LVH) is an independent risk factor for morbidity and mortality from cardiovascular disease in men and women with hypertension and in asymptomatic subjects with normal blood pressure. In hypertensive patients it is a stronger coronary risk factor than casual blood pressure readings. Correlation between levels of high blood pressure, duration of hypertension and Left Ventricular mass is poor. Epidemiological studies suggest that Left Ventricular Hypertrophy may be influenced by genetic factors. In our review we present study groups of genes contributing to the development of Left Ventricular Hypertrophy: 1) genes that encode components of hormonal pathways, 2) genes of key sympathetic and parasympathetic receptors, 3) genes that modify intracellular ion homeostasis, 4) genes that modify energy metabolism, 5) genes that modify motor unit composition and regulation. Angiotensinogen gene, angiotensin-converting enzyme gene, angiotensin receptor type 1 gene, aldosterone synthase gene, nitric oxide synthase gene, type A natriuretic peptide receptor gene, beta(2)-adrenergic receptor gene, G-protein beta(3) subunit gene are associated with Left Ventricular Hypertrophy.

  • Left Ventricular Hypertrophy in hypertension. Part I. Criteria of diagnosis and prevalence
    Kardiologiia, 2020
    Co-Authors: Preobrazhenskiĭ Dv, Alekhin Mn, Sidorenko Ba, Talantbek Batyraliev, Stetsenko Tm
    Abstract:

    : Possibilities of electrocardiography, echocardiography and magnetic resonance tomography for diagnosis of Left Ventricular Hypertrophy are reviewed and various criteria of Left Ventricular Hypertrophy compared. Literature data concerning prevalence of Left Ventricular Hypertrophy in different populations are presented and dependence of reported prevalences of Left Ventricular Hypertrophy on diagnostic technique and criteria is demonstrated. Criteria of dynamic changes of Left Ventricular mass are also discussed.

Biljana Stojimirovic - One of the best experts on this subject based on the ideXlab platform.

  • DIAGNOSTICS AND THERAPY OF Left Ventricular Hypertrophy IN HAEMODIALYSIS PATIENTS
    Serbian Journal of Experimental and Clinical Research, 2020
    Co-Authors: Dejan Petrovic, Nikola Jagic, Vladimir Miloradovic, Aleksandra Nikolic, Biljana Stojimirovic
    Abstract:

    Cardiovascular diseases present a leading cause of death in patients treated with haemodialysis. Th e rate of cardiovascular mortality in this population is approximately 9% on an annual basis, with Left Ventricular Hypertrophy, ischemic heart diseases and heart failure having the highest rates of mortality. Left Ventricular Hypertrophy is present in 75-80 % of haemodialysis-treated patients. Th e most important risk factors for the progression of Left Ventricular Hypertrophy are: hypertension, arteriosclerosis, secondary aortic stenosis, anaemia, increased volume of extracellular fl uid and increased blood fl ow through the vascular access for haemodialysis. Left Ventricular Hypertrophy is present when the Left Ventricular mass index on echocardiography exceeds 131 g/m 2 in males and 100 g/m 2 in females. Left Ventricular Hypertrophy is a risk factor of unfavourable outcome in patients treated with haemodialysis. Th e identifi cation of patients with increased risk of progression of Left Ventricular Hypertrophy, the timely implementation of adequate treatment, and the realisation and maintenance of targeted values of risk factors decelerates the progression of the Hypertrophy and leads to the regression of existing Left Ventricular Hypertrophy, the reduction of cardiovascular morbidity and mortality rates and the improvement of the quality of life of patients treated with haemodialysis.

  • Cardiac troponins and Left Ventricular Hypertrophy in hemodialysis patients
    Medicinski Pregled, 2020
    Co-Authors: Dejan Petrovic, Radmila Obrenovic, Milan Radovanović, Biljana Stojimirovic
    Abstract:

    INTRODUCTION: Cardiovascular diseases are the most frequent cause of death among hemodialysis patients. Left Ventricular Hypertrophy is a potent predictor of cardiovascular morbidity and mortality in those patients. Cardiac troponins (cTnT and cTnI) are indices of myocardial cell damage. The study was aimed to investigate the impact of Left Ventricular Hypertrophy on serum cardiac troponin concentrations. MATERIAL AND METHODS: The study included 115 patients (71 men and 44 women) at the mean age of 53.30+/-12.17 years, treated with regular hemodialyses for 4.51+/-4.01 years, with mean Left ventricle mass index LVMi 143.85+/-41.21 g/m2 and mean Kt/Vsp 1.17+/-0.23. According to echocardiographic findings of the Left ventricle the patients were divided into four groups: the first group included patients with concentric Left Ventricular Hypertrophy, the second group were the patients with eccentric Left Ventricular Hypertrophy, the third group consisted of patients with Left Ventricular dilatation, and the fourth group were patients with normal Left Ventricular morphology. The mean serum troponin T value in the first group was 0.13+/-0.16 ng/ml, in the second group 0.20+/-0.32 ng/ml, in the third group 0.07+/-0.09, and in the fourth group 0.03+/-0.03 ng/ml. RESULTS: Patients with concentric Left Ventricular Hypertrophy showed significantly greater (p

  • Left Ventricular Hypertrophy in patients on hemodialysis: importance of anemia
    Medicinski Pregled, 2020
    Co-Authors: Biljana Stojimirovic, Dejan Petrovic, Radmila Obrenovic
    Abstract:

    INTRODUCTION: Cardiovascular diseases are the most frequent cause of mortality in hemodialysis patients. Left Ventricular Hypertrophy is the main risk factor for development of cardiovascular morbidity and mortality in patients on hemodialysis. Anemia is the only main risk factor for the development of Left Ventricular Hypertrophy in patients on hemodialysis. The aim of this study was to examine the impact of anemia in the development of Left Ventricular Hypertrophy, and correlation between anemia and echocardiographic parameters for the assessment of Left Ventricular Hypertrophy. MATERIAL AND METHODS: The research was conducted on 115 patients (M:F 71:44) regularly treated by hemodialysis, average age 53.30+/-1.2.17 years, average length of dialysis 4.51+/-4.01 years and average Kt/Vsp index 1.17+/-0.23. Depending on the level of hemoglobin, the patients were divided into three groups. The basic parameters investigated were the following: hemoglobin, hematocrite, serum concentrations of albumin, CRP, total cholesterol, HDL cholesterol, LDL cholesterol, and triglyceride serum concentrations, parathormon, diastolic thickness of interVentricular septu-mIVSd, diastolic thickness of Left Ventricular posterior wall, relative wall thickness-RWT, Left Ventricular mass index-LVMi, index of Left Ventricular end-diastolic volume-iLVEDV. The results were statistically analyzed using ANOVA, Kruskal-Wallis test, Student t-test, Mann-Whitney U test, Univariate logistic regression analysis test, and Multivariate logistic regression analysis test. RESULTS: The patients with hemoglobin 100 g/l. The univariate logistic regression analysis has showed that lower HDL cholesterol, anemia, higher systolic arterial pressure and higher mean arterial pressure cumulatively lead to the development of Left Ventricular Hypertrophy. Multivariate logistic regression analysis established anemia as an independent risk factor for the development of Left Ventricular Hypertrophy. CONCLUSION: Anemia is an independent risk factor for the development Left Ventricular Hypertrophy. Identification of patients with increased risk for development of Left Ventricular Hypertrophy and application of appropriate therapy to attain target values of risk factors, result in the regression of Left Ventricular Hypertrophy, reduced cardiovascular morbidity and mortality rates and improved quality of life in patients treated with regular hemodialyses.

  • Left Ventricular Hypertrophy in patients treated with regular hemodialyses
    Medicinski Pregled, 2008
    Co-Authors: Dejan Petrovic, Biljana Stojimirovic
    Abstract:

    : Left Ventricular Hypertrophy is the main risk factor for development of cardiovascular morbidity and mortality in patients on hemodialysis. Left Ventricular Hypertrophy is found in 75% of the patients treated with hemodialysis. Risk factors for Left Ventricular Hypertrophy in patients on hemodialysis include: blood flow through arterial-venous fistula, anemia, hypertension, increased extracellular fluid volume, oxidative stress, microinflammation, hyperhomocysteinemia, secondary hyperparathyroidism, and disturbed calcium and phosphate homeostasis. Left Ventricular pressure overload leads to parallel placement of new sarcomeres and development of concentric Hypertrophy of Left ventricle. Left Ventricular Hypertrophy advances in two stages. In the stage of adaptation, Left Ventricular Hypertrophy occurs as a response to increased tension stress of the Left Ventricular wall and its action is protective. When volume and pressure overload the Left ventricle chronically and without control, adaptive Hypertrophy becomes maladaptive Hypertrophy of the Left ventricle, where myocytes are lost, systolic function is deranged and heart insufficiency is developed. Left Ventricular mass index-LVMi greater than 131 g/m2 in men and greater than 100 g/m2 in women, and relative wall thickness of the Left ventricle above 0.45 indicate concentric Hypertrophy of the Left ventricle. Eccentric Hypertrophy of the Left ventricle is defined echocardiographically as LVMi above 131 g/m2 in men and greater than 100 g/m2 in women, with RWT ?0.45. Identification of patients with increased risk for development of Left Ventricular Hypertrophy and application of appropriate therapy to attain target values of risk factors lead to regression of Left Ventricular Hypertrophy, reduced cardiovascular morbidity and mortality rates and improved quality of life in patients treated with regular hemodialyses.

Stetsenko Tm - One of the best experts on this subject based on the ideXlab platform.

Dejan Petrovic - One of the best experts on this subject based on the ideXlab platform.

  • DIAGNOSTICS AND THERAPY OF Left Ventricular Hypertrophy IN HAEMODIALYSIS PATIENTS
    Serbian Journal of Experimental and Clinical Research, 2020
    Co-Authors: Dejan Petrovic, Nikola Jagic, Vladimir Miloradovic, Aleksandra Nikolic, Biljana Stojimirovic
    Abstract:

    Cardiovascular diseases present a leading cause of death in patients treated with haemodialysis. Th e rate of cardiovascular mortality in this population is approximately 9% on an annual basis, with Left Ventricular Hypertrophy, ischemic heart diseases and heart failure having the highest rates of mortality. Left Ventricular Hypertrophy is present in 75-80 % of haemodialysis-treated patients. Th e most important risk factors for the progression of Left Ventricular Hypertrophy are: hypertension, arteriosclerosis, secondary aortic stenosis, anaemia, increased volume of extracellular fl uid and increased blood fl ow through the vascular access for haemodialysis. Left Ventricular Hypertrophy is present when the Left Ventricular mass index on echocardiography exceeds 131 g/m 2 in males and 100 g/m 2 in females. Left Ventricular Hypertrophy is a risk factor of unfavourable outcome in patients treated with haemodialysis. Th e identifi cation of patients with increased risk of progression of Left Ventricular Hypertrophy, the timely implementation of adequate treatment, and the realisation and maintenance of targeted values of risk factors decelerates the progression of the Hypertrophy and leads to the regression of existing Left Ventricular Hypertrophy, the reduction of cardiovascular morbidity and mortality rates and the improvement of the quality of life of patients treated with haemodialysis.

  • Cardiac troponins and Left Ventricular Hypertrophy in hemodialysis patients
    Medicinski Pregled, 2020
    Co-Authors: Dejan Petrovic, Radmila Obrenovic, Milan Radovanović, Biljana Stojimirovic
    Abstract:

    INTRODUCTION: Cardiovascular diseases are the most frequent cause of death among hemodialysis patients. Left Ventricular Hypertrophy is a potent predictor of cardiovascular morbidity and mortality in those patients. Cardiac troponins (cTnT and cTnI) are indices of myocardial cell damage. The study was aimed to investigate the impact of Left Ventricular Hypertrophy on serum cardiac troponin concentrations. MATERIAL AND METHODS: The study included 115 patients (71 men and 44 women) at the mean age of 53.30+/-12.17 years, treated with regular hemodialyses for 4.51+/-4.01 years, with mean Left ventricle mass index LVMi 143.85+/-41.21 g/m2 and mean Kt/Vsp 1.17+/-0.23. According to echocardiographic findings of the Left ventricle the patients were divided into four groups: the first group included patients with concentric Left Ventricular Hypertrophy, the second group were the patients with eccentric Left Ventricular Hypertrophy, the third group consisted of patients with Left Ventricular dilatation, and the fourth group were patients with normal Left Ventricular morphology. The mean serum troponin T value in the first group was 0.13+/-0.16 ng/ml, in the second group 0.20+/-0.32 ng/ml, in the third group 0.07+/-0.09, and in the fourth group 0.03+/-0.03 ng/ml. RESULTS: Patients with concentric Left Ventricular Hypertrophy showed significantly greater (p

  • Left Ventricular Hypertrophy in patients on hemodialysis: importance of anemia
    Medicinski Pregled, 2020
    Co-Authors: Biljana Stojimirovic, Dejan Petrovic, Radmila Obrenovic
    Abstract:

    INTRODUCTION: Cardiovascular diseases are the most frequent cause of mortality in hemodialysis patients. Left Ventricular Hypertrophy is the main risk factor for development of cardiovascular morbidity and mortality in patients on hemodialysis. Anemia is the only main risk factor for the development of Left Ventricular Hypertrophy in patients on hemodialysis. The aim of this study was to examine the impact of anemia in the development of Left Ventricular Hypertrophy, and correlation between anemia and echocardiographic parameters for the assessment of Left Ventricular Hypertrophy. MATERIAL AND METHODS: The research was conducted on 115 patients (M:F 71:44) regularly treated by hemodialysis, average age 53.30+/-1.2.17 years, average length of dialysis 4.51+/-4.01 years and average Kt/Vsp index 1.17+/-0.23. Depending on the level of hemoglobin, the patients were divided into three groups. The basic parameters investigated were the following: hemoglobin, hematocrite, serum concentrations of albumin, CRP, total cholesterol, HDL cholesterol, LDL cholesterol, and triglyceride serum concentrations, parathormon, diastolic thickness of interVentricular septu-mIVSd, diastolic thickness of Left Ventricular posterior wall, relative wall thickness-RWT, Left Ventricular mass index-LVMi, index of Left Ventricular end-diastolic volume-iLVEDV. The results were statistically analyzed using ANOVA, Kruskal-Wallis test, Student t-test, Mann-Whitney U test, Univariate logistic regression analysis test, and Multivariate logistic regression analysis test. RESULTS: The patients with hemoglobin 100 g/l. The univariate logistic regression analysis has showed that lower HDL cholesterol, anemia, higher systolic arterial pressure and higher mean arterial pressure cumulatively lead to the development of Left Ventricular Hypertrophy. Multivariate logistic regression analysis established anemia as an independent risk factor for the development of Left Ventricular Hypertrophy. CONCLUSION: Anemia is an independent risk factor for the development Left Ventricular Hypertrophy. Identification of patients with increased risk for development of Left Ventricular Hypertrophy and application of appropriate therapy to attain target values of risk factors, result in the regression of Left Ventricular Hypertrophy, reduced cardiovascular morbidity and mortality rates and improved quality of life in patients treated with regular hemodialyses.

  • Left Ventricular Hypertrophy in patients treated with regular hemodialyses
    Medicinski Pregled, 2008
    Co-Authors: Dejan Petrovic, Biljana Stojimirovic
    Abstract:

    : Left Ventricular Hypertrophy is the main risk factor for development of cardiovascular morbidity and mortality in patients on hemodialysis. Left Ventricular Hypertrophy is found in 75% of the patients treated with hemodialysis. Risk factors for Left Ventricular Hypertrophy in patients on hemodialysis include: blood flow through arterial-venous fistula, anemia, hypertension, increased extracellular fluid volume, oxidative stress, microinflammation, hyperhomocysteinemia, secondary hyperparathyroidism, and disturbed calcium and phosphate homeostasis. Left Ventricular pressure overload leads to parallel placement of new sarcomeres and development of concentric Hypertrophy of Left ventricle. Left Ventricular Hypertrophy advances in two stages. In the stage of adaptation, Left Ventricular Hypertrophy occurs as a response to increased tension stress of the Left Ventricular wall and its action is protective. When volume and pressure overload the Left ventricle chronically and without control, adaptive Hypertrophy becomes maladaptive Hypertrophy of the Left ventricle, where myocytes are lost, systolic function is deranged and heart insufficiency is developed. Left Ventricular mass index-LVMi greater than 131 g/m2 in men and greater than 100 g/m2 in women, and relative wall thickness of the Left ventricle above 0.45 indicate concentric Hypertrophy of the Left ventricle. Eccentric Hypertrophy of the Left ventricle is defined echocardiographically as LVMi above 131 g/m2 in men and greater than 100 g/m2 in women, with RWT ?0.45. Identification of patients with increased risk for development of Left Ventricular Hypertrophy and application of appropriate therapy to attain target values of risk factors lead to regression of Left Ventricular Hypertrophy, reduced cardiovascular morbidity and mortality rates and improved quality of life in patients treated with regular hemodialyses.